Telix Pharmaceuticals enters the week before its October earnings with a growing tension between a strong single-day price rebound and a short score that has reached its highest level in recent memory.
The clearest signal right now is the ORTEX short score, which has climbed to 80.2 — up from 76.5 less than two weeks ago and accelerating through each session this week. That kind of consistent, daily grind higher in the short score points to mounting bearish conviction, not a one-day spike. Short interest backs this up: at 10.8% of free float, it represents a meaningful position, and it ticked up again on Tuesday to around 36.7 million shares — roughly 2.4% higher than a week ago and near the top of its recent range. The days-to-cover figure from the most recent official settlement sits at 18.8 days, which is a notably long unwind horizon and adds a structural element to the bear case.
The borrow market is tightening in a way that deserves attention. Availability has dropped sharply — from around 200% of short interest at the start of September to 123% now, nearly halving in three weeks. That's still within the "tight" band rather than extreme, but the direction is unambiguous. Cost to borrow has nearly doubled over the past week, jumping to 2.19% from 1.11%, hitting its highest reading since mid-August. The 52-week peak in borrow demand came when availability reached its tightest at 41.8% — the current trajectory is moving toward that zone, though it hasn't arrived yet. For shorts already in the trade, the cost of carry is rising; for new entrants, the pool of available shares is visibly shrinking.
The Street remains broadly constructive, which makes the short buildup a genuine debate rather than a consensus trade. The analyst consensus is a buy, supported by four outperform ratings against a single hold, with the mean price target at AUD 23.78 — implying roughly 42% upside from Tuesday's close of AUD 16.79. No recent analyst changes appear in the data, so the constructive view has not been revised in response to the short-score deterioration. Valuation is not cheap on conventional metrics — the EV/EBITDA multiple sits near 68x and the trailing P/E is effectively not meaningful for a company at this stage — but the bull case rests on the forward growth story. The 12-month forward EPS growth estimate is tracking well above 300% year-on-year, and the company's EPS surprise factor score ranks in the 77th percentile, suggesting it has historically delivered against forecasts. The factor picture is mixed elsewhere: the short-score rank sits in the 5th percentile, meaning the stock scores worse than 95% of the universe on short-related pressure, while the EPS momentum readings over the past 30 and 90 days are among the weakest in the database.
The ownership register adds a layer of interest. JPMorgan Chase holds nearly 9% of shares — the largest institutional position — and last reported adding over four million shares as of July. CEO Christian Behrenbruch filed a 13G as a 6.97% passive holder in February 2025. The CFO, Darren Smith, made a small open-market purchase of roughly AUD 20,000 worth of shares on September 7, the most recent insider transaction in the data. Neither trade changes the short narrative materially, but the CFO buying in early September — as the short score was beginning its current climb — is worth noting in the context of the overall setup.
The one concrete earnings data point available from the history shows the stock fell roughly 7% on the day of its last result in August, and remained down around the same level five days later. With the next event scheduled for October 15, the question going into that print is whether the short score — now at 80 and still climbing — has already priced in a repeat outcome, or whether the borrow-market tightening signals that bears are still building rather than sitting back.
See the live data behind this article on ORTEX.
Open TLX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
